Daunorubicin hydrochloride

Manufactured by Selleck Chemicals

Sourced in United States

Daunorubicin hydrochloride is a chemical compound used in the production of laboratory equipment. It is a red-orange crystalline powder that is soluble in water and other polar solvents. The compound is typically used in the development and manufacture of various scientific instruments and tools employed in research and analytical settings.

Automatically generated - may contain errors

Lab products found in correlation

Close spelling variants of this product

Daunorubicin (17 citations)

2 protocols using daunorubicin hydrochloride

AML Cell Line Characterization Protocol

Check if the same lab product or an alternative is used in the 5 most similar protocols

All human AML cell lines were purchased directly from recognized repositories; Kasumi-1, MV-4-11, CMK, AML-193, M-07e, HL-60, ML-2, OCI-AML3, ME-1 and HEL from DSMZ (Braunschweig, Germany) and THP-1 from ATCC (Manassas, USA).
AZD6244, PD0325901, GSK1120212, CI-1040, TAK-733, AS703026, MEK162, cytarabine (cytosine arabinoside), daunorubicin hydrochloride (daunorubicin) and etoposide were obtained from Selleck chemicals (Houston, USA). ARRY-162 was purchased from ChemieTek (Indiana, USA). All compounds were dissolved in DMSO and stored at –20° C.

Smith A.M., Zhang C.R., Cristino A.S., Grady J.P., Fink J.L, & Moore A.S. (2019). PTEN deletion drives acute myeloid leukemia resistance to MEK inhibitors. Oncotarget, 10(56), 5755-5767.

+ Open protocol

+ Expand

Validating IDH Mutant Compound Screens

Check if the same lab product or an alternative is used in the 5 most similar protocols

Drug screening was done using IDH inhibitors AGI-5198 (Agios) or BAY-1436032 (Bayer) or the FDA-approved Oncology Drug Set II library (National Cancer Institute) containing 107 compounds. The compounds Gemcitabine hydrochloride (Sigma-Aldrich), Paclitaxel (Sigma-Aldrich), Teniposide (Santa Cruz Biotechnology, Inc), Daunorubicin hydrochloride (SelleckChem), Romidepsin (MedChemExpress), Dactinomycin (BioViotica), Regorafenib (MedChemExpress), Omacetaxine mepesuccinate (Sigma-Aldrich), and Marizomib (Sigma-Aldrich), were selected for the validation studies. Initial NIH compound screens were carried out in a 96-well format on 7 IDH mutant cultures and validation studies were performed in 384-well plates on all 12 IDH mutant cultures using the STARlet automated pipetting system (Hamilton). Serial dilutions of the selected compounds were added after 24 hours and viability was assessed by CellTiter GLO 2.0 after five days. For details see Supplementary Methods.

Verheul C., Ntafoulis I., Kers T.V., Hoogstrate Y., Mastroberardino P.G., Barnhoorn S., Payán-Gómez C., Tching Chi Yen R., Struys E.A., Koolen S.L., Dirven C.M., Leenstra S., French P.J, & Lamfers M.L. (2021). Generation, characterization, and drug sensitivities of 12 patient-derived IDH1-mutant glioma cell cultures. Neuro-oncology Advances, 3(1), vdab103.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!